PBMs are facing new healthcare legislation, which is unlikely to significantly affect prescription drug costs in the US. Full elimination of PBMs wouldn’t greatly reduce drug-related spending, a new report suggests, indicating deeper market changes are necessary to achieve spending reductions. Proposals include changing drug patent protections or amending how drug prices are regulated. The report also stated increased transparency could encourage PBMs to compete more fiercely, impacting profits.
Cyber threat: Where Canada ranks for malware attacks – Canadian Underwriter
Cyber threat: Where Canada ranks for malware attacks Canadian Underwriter
